Lysosomal Storage Diseases Therapeutics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	171 Pages	Coherent Market Insights	June, 2023	CMI18049309

Best Price Guarantee
Price	from $4,500
Length	171 Pages
Publisher	Coherent Market Insights
Published Date	June, 2023
SKU	CMI18049309

Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy (Stem Cell Therapy, Substrate Reduction Therapy, Others)), By Indication (Gaucher's Disease, Fabry Disease, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By End User (Hospitals, Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Lysosomal storage diseases (LSDs) are diseases caused by defects in single-genes. Enzyme defects cause nearly seventy percent of the LSDs, and the rest are defects in enzyme activator or associated proteins. A gene on a particular chromosome locus transcribes a particular enzyme, improper enzyme-coding results in inactive enzymes. Similarly, defective activators result from mutations in activator genes. These conditions cause disease of the organs in which they accumulate and decide the clinical signs and symptoms. Infants and children suffer more severely compared to adults. The clinical features are unique in many children and adults for the same disease. For example, the child's developing brain is more susceptible to insults and manifests symptoms and signs of dysfunction, while this may be milder or absent in adults. Enzyme testing is usually the initial diagnostic test, but genetic analysis of the gene mutations adds precision. There are many modern therapeutic techniques for these conditions. When applied early before organ damage sets in, these therapies have the potential to prevent or delay damage, improve quality of life, and increase lifespan.

Market Dynamics

Increasing significance of lysosomal storage diseases, arrangement of awareness programs by governments and the launch of new products are attributed to the growth of the global lysosomal storage diseases therapeutics market. For instance, on May 11, 2023, Chiesi USA, Inc., a U.S. based pharmaceutical company announced that its product Elfabrio was approved by U.S. Food and Drug Administration. It uses the enzyme pegunigalsidase alfa for enzyme replacement therapy (ERT) to treat adults with confirmed Fabry disease.

Key features of the study:

This report provides an in-depth analysis of the global lysosomal storage diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year

It elucidates potential revaenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global lysosomal storage diseases therapeutics market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., Quest Diagnostics, and Amicus Therapeutics, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global lysosomal storage diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lysosomal storage diseases therapeutics market.

Detailed Segmentation:

Global Lysosomal Storage Diseases Therapeutics Market, By Treatment:

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

Global Lysosomal Storage Diseases Therapeutics Market, By Indication:

Gaucher's Disease

Fabry Disease

Pompe’s Syndrome

Mucopolysaccharidosis

Others

Global Lysosomal Storage Diseases Therapeutics Market, By End User:

Hospitals

Clinics

Global Lysosomal Storage Diseases Therapeutics Market, By Geography:

North America

By Country:

U.S.

Canada

Europe

By Country:

U.K.

Germany

Italy

France

Spain

Russia

Rest of Europe

Asia Pacific

By Country:

China

India

Japan

ASEAN

Australia

South Korea

Rest of Asia Pacific

Latin America

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Middle East:

By Country:

GCC

Israel

Rest of Middle East

Africa

By Country/Region:

Central Africa

South Africa

North Africa

Company Profiles

Shire plc*

Company Overview

Product Portfolio

Financial Performance

Key Strategies

Recent Developments

Pfizer, Inc.

Sanofi SA

BioMarin Pharmaceutical Inc

Actelion Ltd.

Raptor Pharmaceutical Corp.

Protalix Biotherapeutics Inc.

Amicus Therapeutics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Treatment; Market Snapshot, By Indication; Market Snapshot, By End user; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Recent Product Launches; Epidemiology; Merger, Acquisition, and Collaborations; Regulatory Scenario; Key Developments; PEST Analysis
4. Global Lysosomal Storage Diseases Therapeutics Market– COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Lysosomal Storage Diseases Therapeutics Market, By Treatment, 2018–2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018 –2030; Segment Trends; Enzyme Replacement Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Stem Cell Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Substrate Reduction Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
6. Global Lysosomal Storage Diseases Therapeutics Market, By Indication, 2018–2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018 –2030; Segment Trends; Gaucher’s Disease; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Fabry Disease; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Pompe’s Disease; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Mucopolysaccharidosis; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
7. Global Lysosomal Storage Diseases Therapeutics Market, By End user, 2018–2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018 –2030; Segment Trends; Hospitals; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn); Clinics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Bn)
8. Global Lysosomal Storage Diseases Therapeutics Market, By Region, 2018–2030, (US$ Billion): Introduction; Market Share Analysis, By Region, 2023 and 2030 (%); Y-o-Y Growth Analysis, For Regions, 2018 –2030; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 – 2030, (US$ Billion); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Billion); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Billion); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication , 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Billion); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Billion); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018– 2030, (US$ Billion); North Africa; Central Africa; South Africa
9. Competitive Landscape: Shire plc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Pfizer, Inc.; Sanofi SA; BioMarin Pharmaceutical Inc; Actelion Ltd.; Raptor Pharmaceutical Corp; Protalix Biotherapeutics Inc.; Amicus Therapeutics, Inc.; 10. Section; Research Methodology; About Us; *Browse 29 market data tables and 33 figures on “Lysosomal Storage Diseases Therapeutics Market” - Global forecast to 2030